Monitor outcomes to ensure long-term PRRS control success. Track diagnostic results and pig performance data across sow, grow-finish, and whole production systems to detect low-level virus circulation, guide decisions, and move herds toward stable or negative status.
The Guilty Gilt Guide was written with a clear objective – to maximize the whole-herd performance of pig populations by helping gilts to reach their full reproductive potential and produce healthy pigs that reach their full genetic potential during grow-finish.
The open reading frames (ORF)5 represents approximately 4% of the porcine repro- ductive and respiratory syndrome virus (PRRSV)-2 genome (whole-PRRSV) and is often determined by the Sanger technique, which rarely detects >1 PRRSV strain if present in the sample.
Porcine reproductive and respiratory syndrome virus (PRRSV) is an important swine pathogen affecting the global swine industry.
PRRSv remains a very costly desease in pig industry especially in grower finisher pigs1.Vaccination has been demonstrated the cost effective due to reduce of clinical sign and mortality of PRRS infection2. In spite of Type 1-PRRS MLV vaccination have been applied, there’s some introduction of new type 2-PRRSv field infection in grower-finisher farm. Consider of minimize production loss, Ingelvac PRRS MLV has demonstrated efficacy against heterologous PRRSv challenge when pigs already exposed by PRRSv type2 from the field3. The objective of this observation was to evaluate the effect of vaccination by Ingelvac PRRS MLV on the previous exposed in grower-finisher pigs.
PRRS is circulating in about 85% of the Dutch finishing pigs resulting in an estimated loss of 60 grams in ADG during the finishing pig period (1). In a 600 sow head farrow to finish farm with a historical growth of 783 grams/day, Circo-vaccination was implemented. A group of pigs was also vaccinated against PRRS to evaluate its effect on ADG.
PRRS type 1 infections can play a role in finishing pig performance. However, with many pathogens involved in for instance airway infections it is hard to prove which infection is the limiting factor in optimal pig production. The objective of this study is to evaluate the effect of the PRRS type 1 vaccine Ingelvac PRRSFLEX EU®.
Infection with porcine reproductive and respiratory syndrome virus (PRRSV) may lead to significant losses in productivity of breeding and growing pig herds1,2. Performance data was monitored over two years in a commercial farm in Croatia, which faced an acute PRRS outbreak and subsequently implemented changes in the vaccination program. The present abstract presents the results of nursery mortality. Sow performance is presented in a second abstract.